Resumen

FLORIO, Lucía et al. Application of the PROMIS®-dyspnea questionnaire in the monitoring of patients with lymphoma undergoing chemotherapy and a physical exercise plan. Preliminary results from the AEROHEMONCO trial. Rev.Urug.Cardiol. [online]. 2025, vol.40, n.1, e202.  Epub 01-Dic-2025. ISSN 0797-0048.  https://doi.org/10.29277/cardio.40.1.6.

Introduction: the cardiotoxic effect of anthracyclines is defined by the presence of clinical heart failure and/or decreased left ventricular systolic function associated with its use. The PROMIS®-dyspnea questionnaire, which assesses the symptom of dyspnea and its severity, has been extensively validated and suggested for use in clinical trials. However, its use in the cardiotoxicity scenario has not been described.

Objective: to explore the potential usefulness of the PROMIS®-dyspnea questionnaire to detect heart failure or systo-diastolic dysfunction in subjects with lymphoma undergoing chemotherapy who participate in a physical exercise program.

Method: subjects included in the AEROHEMONCO clinical trial (NCT04476576) who completed the chemotherapy plan and 12 weeks of individualized exercise program were included. The PROMIS®-dyspnea questionnaire was administered at the beginning, at 2 and 3 months and at the end of the physical exercise program. Correlation was made between PROMIS®-dyspnea and echocardiographic, clinical, and laboratory variables. Cumulative incidence of cardiotoxicity was calculated.

Results: 19 subjects started chemotherapy for lymphoma; 12 entered AEROHEMONCO and 9 completed the physical exercise program. The questionnaire shows significant variations between measurement stages. The only significant correlation is with hemoglobin value (Spearman rho: - 0.43, p = 0.02). The cumulative incidence of cardiotoxicity in 4 months was 0.22.

Conclusions: in patients with lymphoma undergoing chemotherapy and an exercise program, PROMIS®-dyspnea values vary during follow-up, and may be influenced by the presence and severity of anemia. It is necessary to expand the patient series to define its applicability in order to identify cardiotoxicity in this therapeutic clinical context.

Palabras clave : CARDIOTOXICITY; CHEMOTHERAPY; DYSPNEA; EXERCISE.

        · resumen en Español | Portugués     · texto en Español     · Español ( pdf )